# Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/budget-impact-analysis-of-biosimilar-infliximab-ct-p13-for-the-treatment-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Valentin Brodszky,Petra Baji,Orsolya Balogh,Márta Péntek |
| Citations | 129 |
| DOI | 10.1007/s10198-014-0595-3 |
| Fields | Economics, Econometrics and Finance,Immunology and Microbiology |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://link.springer.com/content/pdf/10.1007/s10198-014-0595-3.pdf |
| OpenAlex ID | https://openalex.org/W1981336058 |
| PMID | 24832837 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Valentin Brodszky](https://scholariq.org/researchers/valentin-brodszky/)

## Paper journal

- [The European Journal of Health Economics](https://scholariq.org/journals/the-european-journal-of-health-economics/)

## Paper primary topic

- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Paper topics

- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Pharmaceutical Economics and Policy](https://scholariq.org/topics/pharmaceutical-economics-and-policy/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.